Thus we reveal that the effectiveness and enhanced cytotoxic action of the combination of HER2 targeted immunotherapeutic agents can be at least partly explained by their ability to cause transcriptional inhibition of NRF2 and greater repression of its antioxidant function in low, moderate and high HER2 expressing ovarian cancer cell lines. This evidence concerns the gene ERBB2 and ovarian cancer.